| Verifiedfields | changed |
|---|---|
| Watchedfields | changed |
| Verifiedrevid | 451565677 |
| Iupac name | (2-Iodophenyl)(1-pentyl-1H-indol-3-yl)methanone |
| Width | 200 |
| Legal ca | Schedule II |
| Legal de | NpSG |
| Legal uk | Class B |
| Cas number | 335160-91-3 |
| Chemspiderid | 25991468 |
| Unii | 61TFT4BO1C |
| C | 20 |
| H | 20 |
| I | 1 |
| N | 1 |
| O | 1 |
| Smiles | Ic1ccccc1C(=O)c(c2ccccc23)cn3CCCCC |
| Stdinchi | 1S/C20H20INO/c1-2-3-8-13-22-14-17(15-9-5-7-12-19(15)22)20(23)16-10-4-6-11-18(16)21/h4-7,9-12,14H,2-3,8,13H2,1H3 |
| Stdinchikey | GAJBHYUAJOTAEW-UHFFFAOYSA-N |
AM-679 (part of the AM cannabinoid series) is a drug that acts as a moderately potent agonist for the cannabinoid receptors, with a Ki of 13.5 nM at CB1 and 49.5 nM at CB2.[1] AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the potent CB1 agonists AM-694 and AM-2233, and the selective CB2 agonist AM-1241.[2] AM-679 was first identified as having been sold as a cannabinoid designer drug in Hungary in 2011, along with another novel compound 1-pentyl-3-(1-adamantoyl)indole.[3]
See also
References
- ^
- ^ Deng H (2000). Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs (PhD Dissertation). University of Connecticut.
- ^ Jankovics P, Váradi A, Tölgyesi L, Lohner S, Németh-Palotás J, Balla J (January 2012). "Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2-iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary". Forensic Science International. 214 (1–3): 27–32. doi:10.1016/j.forsciint.2011.07.011. PMID 21813254